Autopsy report · NCT00506779

Gleevec/Taxol for Patients With Uterine Papillary Serous Carcinoma

“the study was terminated early due to poor enrollment”

The sponsor’s own words in the registry.

Life of this trial

• Registered 3 years 7 months after it had already started.
• Ran for about 11 years 4 months before it stopped.
• 17 participants enrolled.
• Results were posted on the registry 5 years 7 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 1, Phase 2

Sponsor

M.D. Anderson Cancer Center

Sponsor type

University, hospital or other

Conditions

Uterine Cancer

Interventions

Imatinib Mesylate; Paclitaxel

Participants

17

Sites

1

Countries

United States

Trials that died the same way

• A Study of Fuzeon (Enfuvirtide) With an Integrase Inhibitor Plus Optimized Background in Treatment-Experienced HIV-1 Infected Patients
  “This study was terminated early due to poor enrollment.” (98% match in meaning)
• Evaluation of the Consumption of a Probiotic on the Load of S. Agalactiae.
  “The study was terminated due to low enrollment” (97% match in meaning)
• Use of Teriparatide to Accelerate Fracture Healing
  “The study was terminated due to poor enrollment.” (96% match in meaning)
• MIRACLE EF Clinical Study
  “The study was terminated early due to low enrollment.” (96% match in meaning)
• The PRIMO II Study: Paricalcitol Injection Benefits in Renal Failure Induced Cardiac Morbidity in Subjects With Chronic Kidney Disease (CKD) Stage 5
  “This study was prematurely terminated due to low enrollment” (95% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.